English

Eligibility Criteria

5 forms  
  1. StudyEvent: dbGaP phs001002 Metastatic Castration-resistant Prostate Cancer GWAS
    1. Eligibility Criteria
    2. Subject ID, consent group, subject source, source subject ID, and affection status of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
    3. Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
    4. Subject ID, neuropathy, neutropenia, genetic European status, age, sex, hemoglobin, palliative radiation, specimen(s) limitations, blood specimen, ethnicity, race, medical history of participant smoking and venous and arterial thromboembolism, arterial and or venous thromboembolism, BMI, diabetes, gastrointestinal tract, hemorrhage, Khorana risk status, anti-platelet or anti-coagulant use, and treatment arm assignment of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
    5. Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type, and genotyping center of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
Inclusion and exclusion criteria
Description

Inclusion and exclusion criteria

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
CALGB 90401 enrolled 1050 men with metastatic castration-resistant prostate cancer between 2005 and 2007. Among these, 811 patients provided consent for pharmacogenomics studies and usable DNA. The number of patients successfully genotyped was 810.
Description

CALGB 90401 enrolled 1050 men with metastatic castration-resistant prostate cancer between 2005 and 2007. Among these, 811 patients provided consent for pharmacogenomics studies and usable DNA. The number of patients successfully genotyped was 810.

Data type

boolean

Alias
UMLS CUI [1,1]
C5419021
UMLS CUI [1,2]
C4721208
UMLS CUI [1,3]
C0332168
UMLS CUI [2,1]
C0021430
UMLS CUI [2,2]
C1709519
UMLS CUI [2,3]
C5418944
UMLS CUI [2,4]
C0012854
UMLS CUI [2,5]
C1285573
Back to the top of the page

Similar models

Eligibility Criteria

5 forms
  1. StudyEvent: dbGaP phs001002 Metastatic Castration-resistant Prostate Cancer GWAS
    1. Eligibility Criteria
    2. Subject ID, consent group, subject source, source subject ID, and affection status of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
    3. Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
    4. Subject ID, neuropathy, neutropenia, genetic European status, age, sex, hemoglobin, palliative radiation, specimen(s) limitations, blood specimen, ethnicity, race, medical history of participant smoking and venous and arterial thromboembolism, arterial and or venous thromboembolism, BMI, diabetes, gastrointestinal tract, hemorrhage, Khorana risk status, anti-platelet or anti-coagulant use, and treatment arm assignment of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
    5. Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type, and genotyping center of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
CALGB 90401 enrolled 1050 men with metastatic castration-resistant prostate cancer between 2005 and 2007. Among these, 811 patients provided consent for pharmacogenomics studies and usable DNA. The number of patients successfully genotyped was 810.
Item
CALGB 90401 enrolled 1050 men with metastatic castration-resistant prostate cancer between 2005 and 2007. Among these, 811 patients provided consent for pharmacogenomics studies and usable DNA. The number of patients successfully genotyped was 810.
boolean
C5419021 (UMLS CUI [1,1])
C4721208 (UMLS CUI [1,2])
C0332168 (UMLS CUI [1,3])
C0021430 (UMLS CUI [2,1])
C1709519 (UMLS CUI [2,2])
C5418944 (UMLS CUI [2,3])
C0012854 (UMLS CUI [2,4])
C1285573 (UMLS CUI [2,5])
Back to the top of the page